Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.818,20 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A1EWVY8
Filter zurücksetzen
© EQS Newswire
07.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Article
News Preview
Press Release // August 7, 2024   Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences   Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Article
News Preview
Pressemitteilung // 07. August 2024   Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt  Planegg-Martinsried –Die Formycon AG (FWB: FYB, „Formycon“) hat heute Details zur Telefonkonferenz zur Veröffentlichung der Ergebnisse des ersten Geschäfts......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG hebt Prognose für das Geschäftsjahr 2024 an
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Formycon AG hebt Prognose für das Geschäftsjahr 2024 an Planegg-Martinsried, Deutschland, 06. August 2024 – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ("Gesellschaft") hat heute auf Basis der vorläufigen Halbjahreszahlen entschieden, die Prognose für......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
06.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG increases its outlook for the 2024 fiscal year
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG increases its outlook for the 2024 fiscal year Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
30.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Article
News Preview
Press Release // July 30, 2024   Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206  Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab) The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries ......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon gibt Start der klinischen Phase-III-Studie für den Keytruda® Biosimilar-Kandidaten FYB206 bekannt
Article
News Preview
Pressemitteilung // 30. Juli 2024   Formycon gibt Start der klinischen Phase-III-Studie für den Keytruda® Biosimilar-Kandidaten FYB206 bekannt   Phase-III-Studie „Lotus“ vergleicht Sicherheit und Wirksamkeit von FYB206 mit Referenzarzneimittel Keytruda®1 (Pembrolizumab) „Lotus“-Studie sieht Behandlung von rund 500 randomisierten NSCLC2-Patienten......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Article
News Preview
Press Release // July 26, 2024   Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®   Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases in the fields of gastroente......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten positive CHMP-Empfehlung für FYB202 (Ustekinumab), einen Biosimilar-Kandidaten für Stelara®
Article
News Preview
Pressemitteilung // 26. Juli 2024   Formycon und Fresenius Kabi erhalten positive CHMP-Empfehlung für FYB202 (Ustekinumab), einen Biosimilar-Kandidaten für Stelara®   Ausschuss für Humanarzneimittel (CHMP) der europäischen Arzneimittel-Agentur empfiehlt Zulassung von FYB202 für die Behandlung schwerwiegender inflammatorischer Erkrankungen aus den......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Stelara® Biosimilar-Kandidat FYB202 (Ustekinumab) erhält CHMP-Empfehlung der EMA
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Stelara® Biosimilar-Kandidat FYB202 (Ustekinumab) erhält CHMP-Empfehlung der EMA Planegg-Martinsried, Deutschland, 26. Juli 2024 – Die Formycon AG (FWB: FYB, "Formycon“) gibt bekannt, dass der Ausschuss für Humanarzneimittel (Committee for Medicinal Product......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA Planegg-Martinsried, Germany, July 26, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the Committee for Medicinal Products for Human Use („CHMP“) of the Eu......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhält FDA-Zulassung für FYB203/AHZANTIVE®1) (Aflibercept-mrbb), ein Biosimilar für Eylea®2)
Article
News Preview
Pressemitteilung // 01. Juli 2024   Formycon erhält FDA-Zulassung für FYB203/AHZANTIVE®1) (Aflibercept-mrbb), ein Biosimilar für Eylea®2)   Planegg-Martinsried – Die Formycon AG (FWB: FYB, “Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH (“Klinge“) geben bekannt, dass die U.S. Food and Drug Administration (“FDA”) am 28. Juni 2024 die Zulas......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.07.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Article
News Preview
Press Release // July 01, 2024   Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)   Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") approved FYB203/AHZA......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb) Planegg-Martinsried, Deutschland, 28. Juni 2024 – Die Formycon AG (FWB: FYB, "Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH ("Klinge") geben bekannt, dass die U.S......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Eylea®1)- Biosimilar FYB203/AHZANTIVE®2) (Aflibercept-mrbb) Planegg-Martinsried, Deutschland, 28. Juni 2024 – Die Formycon AG (FWB: FYB, "Formycon“) und ihr Lizenzpartner Klinge Biopharma GmbH ("Klinge") geben bekannt, dass die U.S......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports on the results of the Annual General Meeting
Article
News Preview
Press Release // June 13, 2024 Formycon reports on the results of the Annual General Meeting Management provides detailed report on financial year 2023 and current company performance Shareholders approve all agenda items and formally approve the acts of the members of the Management Board and Supervisory Board by large majority Supervisory Boa......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon informiert über die Ergebnisse der ordentlichen Hauptversammlung
Article
News Preview
Pressemitteilung // 13. Juni 2024 Formycon informiert über die Ergebnisse der ordentlichen Hauptversammlung Vorstand berichtet ausführlich über Geschäftsjahr 2023 und aktuelle Unternehmensentwicklung Aktionärinnen und Aktionäre stimmen allen Tagesordnungspunkten zu und entlasten Vorstand sowie Aufsichtsrat mit jeweils großer Mehrheit Aufsichtsr......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH Classification of First Berlin Equity Research GmbH to Formycon AG Company Name: Formycon AG ISIN: DE000A1EWVY8 Reason for the research: Update Recommendation: Buy from: 13.06.2024 Target price: €80,00 Target price on sight of: 12 months Last rating change: - Analyst: Simon Sc......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon startet klinisches Programm für FYB206, einen Biosimilar-Kandidaten für das immun-onkologische Blockbuster-Medikament Keytruda®
Article
News Preview
Pressemitteilung // 13. Juni 2024 Formycon startet klinisches Programm für FYB206, einen Biosimilar-Kandidaten für das immun-onkologische Blockbuster-Medikament Keytruda® Erster Patient in klinische Phase-I-Studie „Dahlia“ zum Vergleich der Pharmakokinetik (PK), Sicherheit und Verträglichkeit von FYB206 mit dem Referenzarzneimittel Keytruda®[i] e......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.06.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Article
News Preview
Press Release // June 13, 2024 Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In). "Dah......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Article
News Preview
Presse Release // May 15, 2024   MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region   Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
Article
News Preview
Presse Release // May 15, 2024   MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region   Planegg-Martinsried – Klinge Biopharma GmbH ("Klinge"), licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon's biosimilar candidate to......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma wird Kommerzialisierungspartner für FYB203, Formycons Eylea® Biosimilar-Kandidat (Aflibercept), in der MENA-Region
Article
News Preview
Pressemitteilung // 15. Mai 2024   MS Pharma wird Kommerzialisierungspartner für FYB203, Formycons Eylea® Biosimilar-Kandidat (Aflibercept), in der MENA-Region   Planegg-Martinsried – Klinge Biopharma GmbH („Klinge"), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat zu Eylea®1 (Aflibe......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma wird Kommerzialisierungspartner für FYB203, Formycons Eylea® Biosimilar-Kandidat (Aflibercept), in der MENA-Region
Article
News Preview
Pressemitteilung // 15. Mai 2024   MS Pharma wird Kommerzialisierungspartner für FYB203, Formycons Eylea® Biosimilar-Kandidat (Aflibercept), in der MENA-Region   Planegg-Martinsried – Klinge Biopharma GmbH („Klinge"), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat zu Eylea®1 (Aflibe......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon berichtet über erfolgreiches operatives Geschäft und Finanzzahlen für das erste Quartal 2024
Article
News Preview
Pressemitteilung // 8. Mai 2024 Formycon berichtet über erfolgreiches operatives Geschäft und Finanzzahlen für das erste Quartal 2024 Konzernumsatz beläuft sich auf 17,7 Mio. € und entspricht Planungen Konzern-EBITDA mit -5,5 Mio. € spiegelt Investitionen in die Produktpipeline und Unternehmensentwicklung wider Bereinigtes Konzern-EBITDA mit -1......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Article
News Preview
Press Release // May 8, 2024 Formycon reports on successful operating business and financial figures for the first quarter of 2024  Group revenue amounts to € 17.7 million and corresponds to plan Group EBITDA of € -5.5 million reflects investments in pipeline and corporate development Adjusted Group EBITDA of € -1.2 million shows strong at-equi......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur ordentlichen Hauptversammlung am 12. Juni 2024 in München ein
Article
News Preview
 Pressemitteilung // 07. Mai 2024 Formycon lädt zur ordentlichen Hauptversammlung am 12. Juni 2024 in München ein Formycon schlägt der Hauptversammlung internationalere Ausrichtung und Erweiterung des Aufsichtsrats auf fünf Mitglieder vor Mit Colin Bond, Dr. Bodo Coldewey und Nicholas Haggar stehen drei neue Kandidaten mit einschlägiger Industri......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Article
News Preview
Press release // 07 May 2024 Formycon invites to the Annual General Meeting on June 12, 2024 in Munich Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon hosts conference call on the results of the first quarter 2024
Article
News Preview
Press Release // May 02, 2024 Formycon hosts conference call on the results of the first quarter 2024 Planegg-Martinsried – Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the first quarter 2024 on May 08, 2024. The management board will discuss the company's developments and key financi......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon veranstaltet Telefonkonferenz zu den Ergebnissen des ersten Quartals 2024
Article
News Preview
Pressemitteilung // 02. Mai 2024 Formycon veranstaltet Telefonkonferenz zu den Ergebnissen des ersten Quartals 2024 Planegg-Martinsried – Die Formycon AG (FWB: FYB, 'Formycon') hat heute Details zur Telefonkonferenz zur Veröffentlichung der Zahlen des ersten Quartals 2024 am 08. Mai 2024 bekannt gegeben. Der Vorstand wird dabei die Entwicklung de......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
Article
News Preview
Press release // April 25, 2024 Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance Preliminary results 2023 confirmed Group revenue increases by 83% compared to the previous year to a total of € 77.7 million Positive Group EBITDA of around € 1.5 million and adj......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon veröffentlicht testierten Jahresabschluss für das Geschäftsjahr 2023 – Rückblick auf ein erfolgreiches operatives Jahr und übertroffene Prognose
Article
News Preview
Pressemitteilung // 25. April 2024 Formycon veröffentlicht testierten Jahresabschluss für das Geschäftsjahr 2023 – Rückblick auf ein erfolgreiches operatives Jahr und übertroffene Prognose Vorläufige Zahlen für 2023 final bestätigt Konzernumsatz steigt im Vergleich zum Vorjahr um 83% auf 77,7 Mio. € Positives Konzern-EBITDA in Höhe von rund 1,5......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
Article
News Preview
Press Release // April 22, 2024   Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024   Munich - Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the financial year 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2024 bekannt
Article
News Preview
Pressemitteilung // 22. April 2024   Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2024 bekannt   München – Die Formycon AG (FWB: FYB, „Formycon“) hat heute Details zur Telefonkonferenz zur Veröffentlichung der Ergebnisse des Geschäftsja......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
Article
News Preview
Press release // 12 April 2024   Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast   Group revenue increase by 83% compared to the previous year to a total of € 77.7 million Positive Group EBITDA of around € 1.5 million achieved New key financial performance indicator (KPI) "......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Überzeugende Gesamtbilanz – Formycon berichtet vorläufige Zahlen für das Geschäftsjahr 2023 und übertrifft Prognose
Article
News Preview
Pressemitteilung // 12. April 2024   Überzeugende Gesamtbilanz – Formycon berichtet vorläufige Zahlen für das Geschäftsjahr 2023 und übertrifft Prognose   Konzernumsatz steigt im Vergleich zum Vorjahr um ca. 83 % auf insgesamt 77,7 Mio. € Positives Konzern-EBITDA in Höhe von rund 1,5 Mio. € verzeichnet Neue Finanzkennzahl „Bereinigtes Konzern-......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year Planegg-Martinsried, Germany, 12. April 2024 – Based on preliminary and unaudited figures for the 2023 financial year, Formycon AG (ISIN: DE000A1......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG veröffentlicht vorläufige Geschäftszahlen für das Geschäftsjahr 2023 und Prognose für das Geschäftsjahr 2024
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Formycon AG veröffentlicht vorläufige Geschäftszahlen für das Geschäftsjahr 2023 und Prognose für das Geschäftsjahr 2024 Planegg-Martinsried, Deutschland, 12. April 2024 – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ("Gesellschaft") erwartet auf Basis......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Article
News Preview
Press release // April 11, 2024   Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)   Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide Lucentis® biosimilar FYB201 is an effective and cost-effi......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.04.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon gibt Markteinführung von FYB201 (Ranibizumab) in Kanada (RanoptoTM) und der Schweiz (Ranivisio®) bekannt
Article
News Preview
Pressemitteilung // 11. April 2024   Formycon gibt Markteinführung von FYB201 (Ranibizumab) in Kanada (RanoptoTM) und der Schweiz (Ranivisio®) bekannt   Kommerzieller Launch erschließt weitere wichtige Märkte in Europa und Nordamerika – FYB201 ist damit in 17 Ländern weltweit verfügbar Lucentis®-Biosimilar FYB201 stellt eine wirksame und kosten......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erzielen Settlement-Vereinbarung für Ustekinumab Biosimilar-Kandidaten FYB202 in Europa und Kanada
Article
News Preview
Pressemitteilung // 18. März 2024   Formycon und Fresenius Kabi erzielen Settlement-Vereinbarung für Ustekinumab Biosimilar-Kandidaten FYB202 in Europa und Kanada   München – Die Formycon AG (FWB: FYB) und ihr Kommerzialisierungspartner Fresenius Kabi gaben heute den Abschluss einer Settlement-Vereinbarung mit Johnson & Johnson für FYB202, e......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.03.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Article
News Preview
Press release // March 18, 2024   Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada   Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the comme......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.03.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FYB201/Ranibizumab nimmt durch Zulassungen und Markteinführungen in MENA-Region weiter Fahrt auf
Article
News Preview
Pressemitteilung // 11. März 2024   FYB201/Ranibizumab nimmt durch Zulassungen und Markteinführungen in MENA-Region weiter Fahrt auf Kommerzialisierungspartner MS Pharma gewinnt staatlichen Tender für Ranibizumab in Saudi-Arabien Vermarktungsstart von FYB201/Ravegza® für zweites Quartal 2024 vorgesehen Weitere geplante Markteinführungen im Lau......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.03.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Article
News Preview
Press release // March 11, 2024   FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region Commercialization partner MS Pharma wins government tender for Ranibizumab in Saudi Arabia Commercial launch of FYB201/Ravegza® planned for second quarter of 2024 Further launches planned throughout 2024 to improve access ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Gedeon Richter becomes strategic investor of Formycon via equity investment
Article
News Preview
Press Release // January 29, 2024 Gedeon Richter becomes strategic investor of Formycon via equity investment Already established trustful collaboration in contract development and manufacturing results in investment through takeover of 9.08% of shares via cash capital increase Gross-proceeds in the amount of EUR 82.84 million to maintain Formyc......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Gedeon Richter wird strategischer Investor von Formycon im Rahmen einer Kapitalbeteiligung
Article
News Preview
Pressemitteilung // 29. Januar 2024 Gedeon Richter wird strategischer Investor von Formycon im Rahmen einer Kapitalbeteiligung Langjährige vertrauensvolle Zusammenarbeit in der Auftragsentwicklung und -herstellung ist Basis der Investition; Beteiligung i.H.v. 9,08 % im Rahmen einer Barkapitalerhöhung Bruttoemissionserlös in Höhe von 82,84 Mio. €......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
Article
News Preview
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Disclosure of i......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon beschließt Barkapitalerhöhung in Höhe von EUR 82,84 Mio. – sämtliche neuen Aktien werden von Gedeon Richter als neuen strategischen Investor gezeichnet
Article
News Preview
NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN DIE BZW. INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN ODER JAPAN SOWIE JEGLICHEN ANDEREN RECHTSORDNUNGEN, IN DENEN DIE VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE RECHTSWIDRIG IST. ES GELTEN WEITERE BESCHRÄNKUNGEN. BITTE BEACHTEN SIE DEN WICHTIG......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
Article
News Preview
Press Release // January 18, 2024   Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023   Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA
Article
News Preview
Pressemitteilung // 18. Januar 2024   Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA   München – Formycon AG (FWB: FYB) gab heute bekannt, dass ihr Vermarktungspartner Coherus BioSciences, Inc.  neue Verkaufszahlen zu CIMERLI®1 (Ranibizumab-eqrn) in den USA veröffentlicht hat. Demn......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Press Release // January 04, 2024   Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference Munich, Germany – Formycon AG (FSE: FYB), a leading, independent developer of high-quality biosimilars, today announced that Formycon CEO Dr. Stefan Glombitza will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on T......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference
Article
News Preview
Pressemitteilung // 04. Januar 2024   Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference München – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), ein führender unabhängiger Entwickler qualitativ hochwertiger Biosimilars hat heute bekannt gegeben, dass Formycon CEO Dr. Stefan Glombitza bei der 42. Annual J.P. Morgan Hea......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.